Olympus reviewed the following literature titled "long-term outcome of the endoscopic submucosal dissection of early gastric cancer: a comparison between patients with and without liver cirrhosis." abstract: gastric cancer (gc) and liver cirrhosis (lc) have high incidence rates, particularly in eastern asia; however, the long-term clinical outcomes or recurrence of gc following endoscopic submucosal dissection (esd) in patients with comorbid lc remain unclear.The present study aimed to compare the long-term efficacy and safety of esd in patients with gc, with and without lc.Patients with early gc (egc) who had underlying lc and underwent endoscopic treatment (lc-egc group) were enrolled in the present study.In addition, patients with egc without lc (non-lc-egc group) were matched at a ratio of 1:3 via propensity score matching.The clinical outcomes and histopathological data of both groups were analyzed.No significant differences were observed in procedure type, complications [intraprocedural bleeding (11.8%) and perforation (0.0%)], en bloc resection rate (94.1%) and complete resection rate (100%) between the two groups.Multivariate cox regression analysis demonstrated that procedure time was significantly associated with procedure-associated bleeding [adjusted hazard ratio (hr), 1.017; 95% confidence interval (ci), 1.001-1.032; p=0.033].Furthermore, lc was significantly associated with cancer recurrence (adjusted hr, 5.482; 95% ci, 1.102-27.279; p=0.038).Taken together, the results of the present study suggest that endoscopic resection of egc in patients with lc is an effective and safe treatment method.However, further studies are required to assess recurrence.Type of adverse events/number of patients: bleeding - 13, perforation - 2, death -1, recurrence -7, this literature article requires 2 reports.The related patient identifiers are as follows: (b)(6) :kd-610l, (b)(6) :gif-h260.This medwatch report is for patient identifier: (b)(6).The death was determined to be not reportable.There is no report of any olympus device malfunction in any procedure described in this study.
|
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, the relationship between the device and the adverse event cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Therefore, the root cause cannot be determined.This supplemental report includes a correction to d8 to provide information that was not included on the initial medwatch.In addition, new information was received from the author and added to b5.Olympus will continue to monitor field performance for this device.
|